UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023 08:57 ET
|
Roivant Sciences
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across...
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023 07:00 ET
|
Roivant Sciences
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across...
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
June 26, 2023 16:05 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00...
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
June 22, 2023 07:30 ET
|
Roivant Sciences
This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved...
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
June 21, 2023 17:00 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM...
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
May 16, 2023 07:00 ET
|
Roivant Sciences
ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10th consecutive positive...
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
March 28, 2023 08:00 ET
|
Roivant Sciences
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement...
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
March 15, 2023 07:45 ET
|
Roivant Sciences
46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with...
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
March 14, 2023 16:07 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00...
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
March 14, 2023 08:00 ET
|
Roivant Sciences
NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative...